Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

27 evidence topics · 6 sources

Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1
Adverse reactionMIPLYFFA with miglustat, N=26, n (%)Placebo with miglustat, N=13, n (%)
Upper respiratory tract infection“8 (31)”“2 (15)”
Diarrhea“6 (23)”“3 (23)”
Decreased weight“4 (15)”“0”
Lower respiratory tract infection“3 (12)”“1 (8)”
Levacetylleucine: recommended dosage by body weight
Body weightMorning doseAfternoon doseEvening dose
15 kg to less than 25 kg“1 gram”“No Dose”“1 gram”
25 kg to less than 35 kg“1 gram”“1 gram”“1 gram”
35 kg or more“2 grams”“1 gram”“1 gram”
Levacetylleucine: adverse reactions in NPC at an incidence of 5% or more in Treatment Period I of Trial 1
Adverse reactionAQNEURSA, N=30, n (%)Placebo, N=30, n (%)
Upper respiratory tract infection“5 (17)”“1 (3)”
Abdominal pain“2 (7)”“0 (0)”
Dysphagia“2 (7)”“0 (0)”
Vomiting“2 (7)”“0 (0)”
Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years
Body surface area (m2)Recommended dose
More than 1.25“200 mg three times a day”
More than 0.88 to 1.25“200 mg twice a day”
More than 0.73 to 0.88“100 mg three times a day”
More than 0.47 to 0.73“100 mg twice a day”
0.47 or less“100 mg once a day”
Miglustat: European Union contraindications, warnings, and precautions

“Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.” (opens the source at this quote in a new tab)

“Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.” (opens the source at this quote in a new tab)

“Gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8).” (opens the source at this quote in a new tab)

“Cases of Crohn’s disease have been reported post-marketing in Niemann-Pick type C disease patients treated with Zavesca.” (opens the source at this quote in a new tab)

“Reliable contraceptive methods should be maintained while male patients are taking Zavesca and for 3 months following discontinuation.” (opens the source at this quote in a new tab)

“The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca.” (opens the source at this quote in a new tab)

“In patients included in the clinical trial, 40%-50% had platelet counts below the lower limit of normal at baseline. Monitoring of platelet counts is recommended in these patients.” (opens the source at this quote in a new tab)

“Growth should be monitored in paediatric and adolescent patients during treatment with Zavesca; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy.” (opens the source at this quote in a new tab)